New combo aims to boost platelets in stubborn ITP

NCT ID NCT04518475

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding rituximab to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) whose platelet counts stay low despite prior treatments. About 224 participants will receive either the combo or eltrombopag alone, and researchers will track platelet counts over 24 weeks. The goal is to find a safer, more effective way to control this bleeding disorder.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eltrombopag and rituximab
What this could lead to: If successful, this combination could offer a more effective way to raise platelet counts and reduce bleeding risk in adults with hard-to-treat ITP.
What could go wrong: This is a phase 4 trial, but the combination may not work better than eltrombopag alone and could increase side effects like infections or liver issues. Results may not apply to all ITP patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura primary thrombocytopenia Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)

Contacts and locations

Locations

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.